About Lyell Immunopharma, Inc.
https://www.lyell.comLyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness.
CEO
Richard D. Klausner
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2025-06-02 | Reverse | 1:20 |
ETFs Holding This Stock
Summary
Showing Top 3 of 32
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Grade Summary
Showing Top 1 of 1
Price Target
Institutional Ownership
APOLETTO LTD
Shares:15.09M
Value:$354.1M
BLACKROCK INC.
Shares:13.5M
Value:$316.6M
WUXI APPTEC CO., LTD.
Shares:7.39M
Value:$173.39M
Summary
Showing Top 3 of 70
About Lyell Immunopharma, Inc.
https://www.lyell.comLyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $15K ▲ | $37.27M ▼ | $-38.85M ▲ | -258.97K% ▲ | $-2.13 ▲ | $-36.28M ▲ |
| Q2-2025 | $8K ▲ | $47.15M ▼ | $-42.68M ▲ | -533.55K% ▲ | $-2.89 ▼ | $-42.56M ▲ |
| Q1-2025 | $7K ▼ | $57.37M ▼ | $-52.2M ▲ | -745.64K% ▲ | $-0.18 ▲ | $-53.93M ▲ |
| Q4-2024 | $11K ▼ | $201.16M ▲ | $-191.94M ▼ | -1.74M% ▼ | $-0.72 ▼ | $-57.64M ▼ |
| Q3-2024 | $34K | $50.54M | $-44.58M | -131.13K% | $-0.17 | $-45.83M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $319.62M ▲ | $407.96M ▲ | $78.84M ▼ | $329.12M ▲ |
| Q2-2025 | $276.79M ▼ | $385.45M ▼ | $86.53M ▼ | $298.92M ▼ |
| Q1-2025 | $301.18M ▼ | $429.8M ▼ | $93.28M ▼ | $336.52M ▼ |
| Q4-2024 | $370.53M ▼ | $490.86M ▼ | $108.03M ▲ | $382.82M ▼ |
| Q3-2024 | $440.55M | $619.22M | $88.52M | $530.7M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-38.85M ▲ | $-28.58M ▲ | $3.35M ▼ | $50M ▲ | $24.77M ▲ | $-28.64M ▲ |
| Q2-2025 | $-42.68M ▲ | $-34.46M ▲ | $12.65M ▼ | $183K ▲ | $-21.63M ▼ | $-34.63M ▲ |
| Q1-2025 | $-52.2M ▲ | $-54.74M ▼ | $69.47M ▲ | $1K ▼ | $14.73M ▲ | $-54.98M ▼ |
| Q4-2024 | $-191.94M ▼ | $-47.24M ▼ | $53.51M ▲ | $437K ▲ | $5.3M ▲ | $-47.29M ▼ |
| Q3-2024 | $-44.58M | $-35.04M | $1.92M | $0 | $-33.12M | $-35.1M |
Revenue by Products
| Product | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|
 Reportable segment | $0 ▲ | $0 ▲ | $0 ▲ |
CEO
Richard D. Klausner
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2025-06-02 | Reverse | 1:20 |
ETFs Holding This Stock
Summary
Showing Top 3 of 32
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Grade Summary
Showing Top 1 of 1
Price Target
Institutional Ownership
APOLETTO LTD
Shares:15.09M
Value:$354.1M
BLACKROCK INC.
Shares:13.5M
Value:$316.6M
WUXI APPTEC CO., LTD.
Shares:7.39M
Value:$173.39M
Summary
Showing Top 3 of 70